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Abstract
Wnt signaling is crucial for a variety of biological processes, including body axis formation, planar polarity, stem cell
maintenance and cellular differentiation. Therefore, targeted manipulation of Wnt signaling in vivo would be extremely
useful. By applying chemical inducer of dimerization (CID) technology, we were able to modify the Wnt co-receptor, low-
density lipoprotein (LDL)-receptor-related protein 5 (LRP5), to generate the synthetic ligand inducible Wnt switch, iLRP5. We
show that iLRP5 oligomerization results in its localization to disheveled-containing punctate structures and sequestration of
scaffold protein Axin, leading to robust b-catenin-mediated signaling. Moreover, we identify a novel LRP5 cytoplasmic
domain critical for its intracellular localization and casein kinase 1-dependent b-catenin signaling. Finally, by utilizing iLRP5
as a Wnt signaling switch, we generated the Ubiquitous Activator of b-catenin (Ubi-Cat) transgenic mouse line. The Ubi-Cat
line allows for nearly ubiquitous expression of iLRP5 under control of the H-2K
b promoter. Activation of iLRP5 in isolated
prostate basal epithelial stem cells resulted in expansion of p63
+ cells and development of hyperplasia in reconstituted
murine prostate grafts. Independently, iLRP5 induction in adult prostate stroma enhanced prostate tissue regeneration.
Moreover, induction of iLRP5 in male Ubi-Cat mice resulted in prostate tumor progression over several months from
prostate hyperplasia to adenocarcinoma. We also investigated iLRP5 activation in Ubi-Cat-derived mammary cells, observing
that prolonged activation results in mammary tumor formation. Thus, in two distinct experimental mouse models,
activation of iLRP5 results in disruption of tissue homeostasis, demonstrating the utility of iLRP5 as a novel research tool for
determining the outcome of Wnt activation in a precise spatially and temporally determined fashion.
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Introduction
Wnt signaling exerts diverse biological effects in an organism,
such as body axis determination during embryogenesis, cell
polarity induction and stem cell self-renewal [1]. Mutations that
result in the over-activation of the Wnt signaling axis have been
identified in many cancers and shown to play critical roles in
tumorigenesis [2,3]. Due to the central importance of Wnt
signaling in development and maintenance of tissue homeostasis,
molecular interactions involved with Wnt pathway induction and
its final physiological outcome have been widely investigated. To
date, there are 19 known Wnt ligands and 10 different frizzled (Fz)
family Wnt receptors identified in mammals. Additionally, there
are several Wnt co-receptors, such as lipoprotein receptor-related
protein (LRP)-5/6, the axon guidance protein, Receptor related to
tyrosine kinase (Ryk) and ROR1/2 [4,5,6]. The combinatorial
interactions of these diverse proteins likely result in a vast array of
biological effects. Wnt signaling may be propagated through the
canonical Wnt/b-catenin pathway or via numerous ‘‘non-
canonical’’ signaling pathways, affecting disparate targets, such
as planar cell polarity, Jun kinase (JNK) activation or intracellular
calcium levels.
Association of Wnt ligand to its receptor/co-receptor complex
initiates canonical Wnt signaling. In the absence of Wnt ligands,
the b-catenin ‘‘destruction complex’’ comprising Axin, adenoma-
tosis polyposis coli (APC) and GSK-3b, sequesters and phosphor-
ylates the canonical Wnt signal transducer, b-catenin. Phosphor-
ylated b-catenin is targeted for ubiquitination and proteasomal
degradation. Hence, in the unliganded state, the cytoplasmic pool
of b-catenin is maintained at low levels. Upon association of a Wnt
ligand to an appropriate Fz receptor and co-receptor LRP5/6, the
regulatory protein Dishevelled (Dvl) becomes activated via
phosphorylation. Activated Dvl triggers disruption of the destruc-
tion complex, allowing for nuclear accumulation of b-catenin,
where it interacts with the LEF/TCF complex, resulting in the
transcription of Wnt target genes.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30814Due mostly to lipid modifications, purification of Wnt proteins
has proven to be technically challenging. Therefore, in order to
reproduce Wnt activation in experimental settings, various
strategies have been developed to selectively stabilize or upregulate
b-catenin expression. Although in vitro experiments have many
practical benefits, such as typically shorter duration and high
throughput data analysis, the complexity of multi-lineage systems
attainable in genetically engineered mouse (GEM) models often
provides a more physiologically relevant understanding of a
particular biological process. Since the technique was developed in
the early 1980s, many transgenic mouse models have been
characterized. Manipulation of regulatory pathways, via selective
gene regulation in transgenic models, has provided important
insights into tumor development and cancer biology. More recent
‘‘conditional’’ technologies, such as Cre-Lox recombination or
tamoxifen-inducible transcriptional regulation, have added tem-
poral control of in vivo gene manipulation. These systems have
proven to be especially useful in models where alteration of a
biological pathway may result in embryonic lethality. However,
reversible regulation of gene expression or protein function can
provide an additional dimension of control to permanent Cre-Lox-
induced changes.
The importance of Wnt signaling in tumor biology has led to a
keen interest in dissecting and identifying key regulatory
components. The mouse mammary tumor virus (MMTV)-based
tumor model provided initial insight into the importance of Wnt
signaling in the regulation of tissue homeostasis. Int-1 (Wnt1) was
the first gene discovered to be activated by an integrated provirus
in the MMTV tumor models [7]. Following the discovery of Wnt1,
numerous Wnt pathway-targeted knockout mouse models have
been developed in order to decipher the molecular details of Wnt
signaling [8]. Moreover, by taking advantage of the Cre-Lox
system, multiple mouse models have been engineered that also
permit spatiotemporal control of Wnt signaling activation. One
such method utilized the conditional inactivation of APC to
simulate Wnt signaling activation. Conditional deletion of exon 14
in the APC
580S/580S mouse model (APC
flox/flox) promoted
adenoma formation in the colorectal region by 4 weeks of age
[9]. In a separate study, prostate-targeted, probasin-Cre
+ (PB-
Cre
+) mice were crossed with APC
flox/flox to generate PB-Cre
+;
APC
flox/flox. These mice allow for the inactivation of APC
specifically within prostate epithelial cells, leading to development
of prostate adenocarcinoma within 7 months [10], again consistent
with a key role for b-catenin in tumor progression.
A second method for conditional activation of Wnt signaling
involves stabilization of b-catenin by excising a portion of exon 3,
the target of phosphorylation and subsequent ubiquitination and
degradation. Transgenic mice expressing conditionally activated
b-catenin in neural precursors develop enlarged brains and
increased cerebral cortical surface area [11]. In prostate
epithelial-targeted b-catenin activation models, prostate tumor
formation occurs, although the kinetics is slower than in the APC
KO model [12,13]. Together, these mouse models have expanded
our knowledge of aberrant Wnt signaling activity in various tissues.
Considering the prevalence of Wnt signaling-based mouse
models that are constitutively active, we opted to develop an
inducible canonical Wnt signaling system that utilizes the more
versatile chemical inducer of dimerization (CID)-based ‘‘on/off’’
system. Toward this goal, we performed CID-based oligomeriza-
tion of several components of Wnt signaling and discovered that
inducible multimerization of the cytoplasmic domains of the Wnt
coreceptors, LRP5 and LRP6, could emulate canonical Wnt
signaling, without the potentially confounding effects of LRP5/6
interaction with Wnt inhibitors, Dickkopf proteins (DKKs) and
sclerostin (SOST) [14,15]. Inducible LRP5 (iLRP5), comprises the
cytoplasmic portion of LRP5 fused to the CID-binding domain,
FKBP12(V36) (Fv). Like a ‘‘true’’ switch, iLRP5 has the ability to
be turned on and off by the simple addition or removal of CID,
AP20187, resulting in potent canonical Wnt pathway induction.
To better understand the disparate outcomes of ß-catenin
induction in physiological settings, we used the broadly active
major histocompatibility complex I (MHC-I) promoter (H-2K
b)t o
express iLRP5 and a coupled click beetle (species) red-shifted
luciferase reporter (CBR) gene. This allowed for the near
ubiquitous expression of iLRP5, as well as bioluminescence
imaging in live tissues. Initially, we have analyzed the consequence
of Wnt activation via iLRP5 dimerization in mammary and
prostate tissue systems. Both of these systems exhibited highly
reproducible CID-dependent hyperplasia and in some instances
tumorigenesis. These transgenic mice, named Ubiquitous Activa-
tor of b-catenin (or ‘‘Ubi-Cat’’), should, therefore, provide a
valuable research tool for controlled induction of the Wnt pathway
in various tissues.
Results
Synthetic recruitment of LRP5/6 to lipid rafts leads to
inducible b-catenin regulation
Consistent with plasma membrane-anchored LRP5/LRP6
variants, lipid raft targeting of the intracellular domains of LRP5
and LRP6 (MF-LRP5c and MF-LRP6c) constitutively activates b-
catenin signaling in mammalian cells, suggesting that membrane
localization of the signaling domain of LRP5/LRP6 is a major
determinant for b-catenin induction [16,17,18,19](Fig. S1).
Therefore, we reasoned inducible recruitment of the cytoplasmic
domain of LRP5/LRP6 to membrane lipid rafts might result in
reversible regulation of signaling. To test this, we fused the LRP5
cytoplasmic domain to three tandem rapamycin-binding
FKBP12(P89, K90) domains [20], generating F3-LRP5c. As a
lipid raft-docking protein, we fused the myristoylation-targeting
domain of c-Fyn (MF) to tandem copies of the mutant, 89-amino
acid, rapamycin-binding domain from mTOR (mammalian target
of rapamycin; FRB(L2098)/FRBl) [21]. Upon administration of
membrane-permeable rapamycin analogs (‘‘rapalogs’’) [20] to cells
co-expressing F3-LRP5c and MF-FRBl2, b-catenin signaling is
induced, as determined using the TCF4/b-catenin-responsive
reporter, TCF-SEAP (Fig. 1, left panels). However, the
signaling level was lower than permanently lipid raft-‘‘anchored’’
LRP5 (MF-LRP5c), suggesting that membrane translocation alone
is not sufficient for maximal b-catenin induction.
During lipid raft targeting, the high local concentration of
proteins that occurs likely leads to increased incidental protein
aggregation that could contribute to activation of signaling.
Therefore we tested the hypothesis that further regulated
oligomerization of membrane-targeted F3-LRP5c might further
enhance b-catenin activation (Fig. 1, top right). Indeed, in
addition to low-level b-catenin induction achieved by membrane
localization, further dimerization (or oligomerization) of LRP5
cytoplasmic domains, via dimeric FK506, FK1012 [22], resulted
in an increased level of b-catenin signaling (Fig. 1, bottom
right), suggesting that synthetic dimerization of LRP5 recapitu-
lates the reported functional role of LRP5/6 clustering and
activation [23].
Intracellular dimerization of LRP5c is sufficient to induce
canonical Wnt signaling in an Axin-dependent manner
Several reports have shown that LRP5 phosphorylation by
membrane-associated kinases, such as CK1c and GSK3b,i s
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signaling, again suggesting membrane targeting of LRP5 is critical
[24,25]. Therefore, to determine if the observed dimerization-
dependent LRP5c signaling requires membrane localization, we
dimerized non-targeted LRP5c. Surprisingly, we observed that
administration of FK1012 to cells transfected with F3-LRP5c
alone (without docking protein MF-FRBl2), led to robust b-catenin
induction, indistinguishable to that achieved by dimerization (or
oligomerization) of membrane-localized F3-LRP5c (Fig. 2A, open
square). This suggested the possibility that LRP5 oligomerization
is sufficient for b-catenin stabilization and that membrane-
localization may be necessary only to facilitate ligand-receptor
interactions. To further assess this observation, we redesigned
iLRP5 using the ‘‘second generation’’ CID-binding domain,
FKBP12(V36) (‘‘Fv’’), that responds to FKBP12v36 (Fv)-selective
CID, AP20187 (or clinical candidate AP1903) [26]. Consistently,
simple multimerization of the cytoplasmic signaling domain of
LRP5 led to potent induction of b-catenin activation, regardless of
the lack of a classical membrane-targeting sequence (data not
shown).
It has been well documented that sequestration of Axin from the
destruction complex by membrane-bounded LRP5 is a key step
for b-catenin induction (16). Therefore, we tested whether
interaction with Axin by dimerized iLRP5 is required for b-
catenin activation. Co-expression of Axin with MF-LRP5c or
iLRP5 completely abrogated both MF-LRP5c- and iLRP5-
mediated b-catenin activation, respectively (Fig. 2B, S2). In
addition, dimerization of cytoplasmic iLRP5 induced the interac-
tion of dimerized iLRP5 and Axin, suggesting that Axin is a critical
downstream target of endogenous LRP5, as well as iLRP5
(Fig. 2C).
Dimerized LRP5 co-localizes with Dvl but induces b-
catenin in a Dvl and Axin-dependent manner
Although dimerized F3-LRP5c could stabilize b-catenin without
direct membrane localization, we could not rule out that
dimerization of LRP5c had conferred increased membrane
affinity, possibly due to Fz/Dvl complexes, consistent with the
putative role for Dvl in LRP6 aggregation in the plasma
membrane [23]. Rather than increasing plasma membrane
localization, however, we found that dimerization of F3-GFP-
LRP5c (containing an eGFP domain to permit direct visualization)
induced a punctate, cytoplasmic pattern, suggesting that dimerized
LRP5c might associate with intra-cytoplasmic membrane com-
partments, possibly containing the Fz/Dvl receptor complex
(Fig. 3A). Further studies showed that these iLRP5-containing
punctate structures did not overlap with endosomes or lysosomes
(data not shown), but instead co-localized with Dvl-containing
punctate structures in the cytoplasm (Fig. 3B). To demonstrate
this, we fused red fluorescence protein (RFP) to full-length Dvl to
produce Dvl-RFP and examined subcellular expression with or
without F3-GFP-LRP5c. Interestingly, Dvl-RFP specifically co-
localized with F3-GFP-LRP5c only after dimerization of LRP5c,
but not in control cells, suggesting that active and dimerized
LRP5c translocates to unique Dvl-containing punctate structures.
Although Dvl has been reported to associate with Frizzled
receptors (Fz) during Fz-mediated Wnt signaling, it remains
unresolved whether iLRP5-mediated b-catenin signaling is also
Dvl-dependent. Previous findings have revealed the importance of
Dvl in mediating LRP6-signalosome assembly [23]. Therefore, we
were interested in a possible role of Dvl in iLRP5-mediated Wnt
signaling activation. Therefore, we tested whether a dominant-
negative Dvl allele, comprising primarily the Axin-binding, N-
terminal DIX domain of Dvl, could affect iLRP5-mediated b-
catenin activation. Although 0.2 mg of Axin expression vector
almost completely blocked iLRP5 activity, 0.5 mg of DIX
expression vector showed only a partial inhibition of iLRP5-
mediated b-catenin activation (Fig. 3C). In addition, co-
expression of iLRP5 and Dvl showed moderately additive effects
on b-catenin activation, suggesting that although iLRP5 translo-
cates to intracellular Dvl-containing punctate structures, iLRP5-
mediated Axin-b-catenin signaling may still involve Dvl as part of
the iLRP5 signalosome (Fig. 3D). Finally, in order to ensure that
the above observations are not due to inconsistencies in DNA
Figure 1. LRP5 forms constitutive dimers and CID-mediated dimerization of LRP5 induces TCF/b-catenin activity. Schematics (top) and
TCF reporter activity (bottom) of CID-mediated membrane translocation (A) with dimerization (B) of the LRP5 cytoplasmic domain (LRP5c). 293 cells
were transiently transfected with TOP-SEAP reporter plasmid along with plasmids encoding myristoylated LRP5c (MF-LRP5c) or lipid raft-docking
construct, MF-FRBl2, along with either LRP5c fused to 3 tandem rapalog-binding domains (F3-LRP5c) or control protein, F3-eGFP. TOP-SEAP activity
was measured 24 hours after administration of indicated amounts of Rapalog-B (Rap-B) (A) or homodimer (FK1012) along with suboptimal levels of
Rap-B (50 nM) (B). Protein expression levels are indicated by anti-HA western blot (inset).
doi:10.1371/journal.pone.0030814.g001
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was examined via Western blot analysis (Fig. S3).
CK1 is a critical downstream regulator of iLRP5-mediated
b-catenin activation
Previous reports suggested LRP5 activation is regulated by
phosphorylation of its cytoplasmic domain by membrane-associ-
ated CK1c. [24,25]. However, we observed that CID-activated
iLRP5 is localized in the cytoplasm yet still highly functional. In
order to test whether CK1c is also required for iLRP5-mediated b-
catenin activation, we first tested the effects of CK1 inhibition
using CK1-i. Although p42/44 MAPK, PI3K and Akt inhibitors
(i.e. PD98059, wortmannin, and Akt-i, respectively) did not inhibit
CID-dependent iLRP5 activity, the CK1 inhibitor, CK1-i, clearly
blocked iLRP5-mediated b-catenin activation in a dose-dependent
fashion. Similar CK1-i levels had no effect on hCD40/CD40L-
mediated NF-kB activation (Fig. 4). These results support that
both dimerization of LRP5c and CK1 activity are required for
iLRP5-mediated b-catenin activation.
Both a novel region (1516–1531) of LRP5 and CK1
phosphorylation sites are critical for iLRP5 function and
subcellular localization
It has been proposed that plasma membrane-associated CK1c
phosphorylates two Ser/Thr-containing motifs in LRP6 [24].
Therefore, to further define the potential role of CK1 phosphor-
ylation sites in iLRP5, corresponding to CK1-targeted sites in
LRP6, we designed a deletion series of iLRP5 constructs and
tested them for b-catenin-inducing ability. These included full-
length iLRP5c (LRP51408–1615) and iLRP5D1 (LRP51456–1615)
containing two potential CK1 sites, iLRP5D2 (LRP51490–1615)
containing one CK1 site, and iLRP5D3 (LRP51515–1615), iLRP5D4
(LRP51532–1615) and iLRP5D5 (LRP51553–1615) containing only
‘‘PPPSP’’ consensus sites without CK1 sites. Interestingly, we
observed that the deletion of just one CK1 site in iLRP5
dramatically reduced b-catenin activation (compare iLRP5D1
and D2; Fig. 5A, B). However, the deletion of a second CK1 site
found in iLRPD2 [24] did not further affect iLRP5-mediated
Wnt/b-catenin signals, showing indistinguishable activity com-
pared with iLRP5D3( Fig. 5A). Instead, the further deletion of a
previously unidentified region of LRP5 (1516MFYSSNIPATVR-
PYRPY1531) in constructs iLRP5D4 and iLRP5D5, which do not
carry any consensus CK1 phosphorylation sites [24], completely
abolished residual Wnt/b-catenin activity, suggesting that the
phosphorylation of iLRP5 by CK1 and additional factor(s)
targeting adjacent regions are critical for iLRP5 function.
Subsequent co-immunoprecipitation studies between iLRP5
mutants and Axin revealed that the deletion of CK1 motifs and a
domain (1516–1531) in iLRP5D4 and iLRP5D5, which contain at
leastthreePPPSPmotifs,alsowascorrelativewithdownregulationof
the Axin/iLRP5 interaction, suggesting that a possible defect of
PPP(S/T)P phosphorylation in iLRP5 deletion mutants contributes
to reducing Axin/iLRP5 interaction (Fig. 5B). Therefore, to further
clarify the phosphorylation status of iLRP5 mutants after dimeriza-
tion, we performed western analysis with anti-pS1490 antibody,
which can specifically recognize the phosphorylated PPPSP motif,
needed for Axin interaction (Fig. S4). Interestingly, both truncated
LRP5-D2 and LRP5-D5 were constitutively phosphorylated even
without dimerization, indicating that dimerization and CK1
phosphorylationratherthanphosphorylationofPPP(S/T)Pdomains
in LRP5 is required to induce iLRP5-mediated b-catenin activation.
To further examine the possible correlation of iLRP5c or
iLRP5c mutants with their subcellular localization, GFP fusion
proteins with LRP5c deletion mutants were generated. Consis-
tently, iLRP5D1 dimerization induced the distinct punctate
cytoplasmic structures (similar to those observed with iLRP5c),
whereas dimerization of iLRP5D2 and iLRP5D5 showed progres-
sive loss of subcellular localization (iLRP5D3 showed the same
pattern as iLRP5D2), indicating that re-localization to punctate
structures after dimerization of iLRP5 exhibited a strong
correlation with subsequent b-catenin activation (Fig. 5C).
The previously unidentified region of LRP5 (1516MFYSSNI-
PATVRPYRPY1531) appears to possess important residues
required for full iLRP5/Wnt signaling. Sequence homology
analysis of this LRP5-derived region from various species as well
as a comparison to highly homologous and functionally related co-
Figure 2. Axin is a critical downstream regulator of iLRP5 and
interacts with iLRP5. (A) Effects of dimerization and membrane
translocation of LRP5c on Wnt/b-catenin signaling. Activation of the TCF
reporter in 293 cells transiently transfected with 1 mg each TCF-SEAP
reporter and MF-LRP5c (#), MF-FRBl2+F3-GFP (N), F3-LRP5c (%)o rM F-
FRBl2+F3-LRP5c (&) expression plasmids is shown. After 24 hours, cell
aliquots were treated with CID and suboptimal (5 nM) Rap-B, and SEAP
activity was measured after 24 hours. (B) Effect of Axin on iLRP5-
mediated b-catenin activation. 293 cells were transiently transfected
with 1 mg each of TCF-SEAP and iLRP5 plasmids with our without myc-
tagged Axin. After 24 hours, cells were treated with 100 nM CID
(AP20187) or diluent alone, and SEAP activity was measured after an
additional 24 hours. Protein expression levels were determined by anti-
myc and anti-HA blotting (inset). (C) Dimerization-dependent interac-
tion of Axin and iLRP5. 293 cells were transfected with 1 mg of indicated
combinations of iLRP5 and Axin. After treatment with 100 nM
homodimer (AP20187) for 24 hours (lane 2, 4), whole cell lysates were
immunoprecipitated with anti-myc antibody (myc). Co-immunoprecip-
itation of LRP5c was analyzed by anti-HA blot (HA). Backbone (Fv9-Fvls-
HA) or iLRP5 (Fv9-Fvls-iLRP5-HA) protein expression was detected by
anti-HA blot (Input: HA). All data are representative of at least two
(panel A) or three (panels B–C) independent experiments with similar
results. Error bars (B) represent S.D. of triplicate measurements.
doi:10.1371/journal.pone.0030814.g002
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Interestingly, two highly conserved subregions within the sequence
(YSS and YRPY) contain possible phosphorylation target sites, thus
helpingto target a limited mutagenesis study. Initially, we generated
three membrane-targeted MF-hLRP5 variants, utilizing the lipid
raft-targeting amino terminus of c-Fyn. In one, we replaced Y1518
with phenylalanine and adjacent serines with alanines [Y1518F;
S1519A; S1520A]. In a second, YRPY sequence was altered to
FLPF [Y1529F; R1530L; Y1531F] and the third clone possessed
both FAA and FLPF mutant sequences. A TCF-reporter assay was
used to measure constitutive canonical Wnt signaling of all 3
mutants relative to MF-hLRP5, containing the unmutated sequence
(Fig. 6B). Curiously, although both FAA and FLPF mutants
revealed reduced activity, the double-cluster mutant, containing
FAA and FLPF residues had similarly reduced activity, possibly due
to the inclusion of colocalized, endogenous LRP5 (or 6) in signaling-
competent multimers.
To further dissect the importance of YSS and YRPY sequences,
we generated three iLRP5 variants carrying the previously
described mutations. We reasoned that non-membrane-localized
iLRP5 variants would be less likely to interact with endogenous
sequence. Interestingly, FAA, FLPF and FAA/FLPF double
mutants now demonstrated distinct levels of Wnt activation upon
cytosolic dimerization (Fig. 6C). Whereas, the FAA and, to a
lower extent, FLPF mutants demonstrated reduced b-catenin
inducibility, the double mutant variant was completely inactive
upon dimerization (Fig. 6C). Overall, the above observation
emphasizes the importance of the previously unidentified LRP5
(1516MFYSSNIPATVRPYRPY1531) region for iLRP5 activity as
well as for full activity of membrane-targeted MF-hLRP5, designed
to approximate endogenous LRP5 function.
Ubi-Cat Transgenic Mice
In order to investigate the physiological relevance of the iLRP5
switch as a Wnt signaling activator, we designed transgenic mice,
termed ‘‘Ubiquitous expression of inducible b-Catenin (Ubi-Cat)’’.
To affect broad somatic cell expression of iLRP5, we utilized the H-
2K
b (MHC- class I) promoter [27]. Initially, we examined Wnt
Figure 3. Dimerized-iLRP5 localizes to disheveled-containing punctate structures. (A, B) Subcellular localization of dimerized LRP5c and
disheveled. 293 cells were transfected with 1 mg each of plasmids expressing drug-binding domains fused with GFP (F3-GFP) or GFP-LRP5c (F3-GFP-
LRP5c) with (B) or without (A) RFP-fused disheveled construct, Dvl-RFP. Twenty-four hours after transfection, 100 nM FK1012 was added for an
additional 24 hours to induce F3-LRP5c dimerization. After fixation, cells were labeled with cholera toxin B (CTx-B-TRITC) (A) and examined by
fluorescence microscopy. (C, D) Independent role of iLRP5 and disheveled in b-catenin activation. 293 cells were transfected with 1 mg TCF-SEAP
reporter along with 0.5 mg of iLRP5 and the indicated amounts (mg) of Axin or dominant negative disheveled (Dix) constructs (C) or 0.5 mg disheveled
construct (D). Twenty-four hours after transfection, 100 nM CID was added and SEAP activity was measured after 24 hours. Data is representative of
at least three independent experiments (A, B). Error bars indicate mean 6 S.D. of triplicate measurements (C. D).
doi:10.1371/journal.pone.0030814.g003
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a standard reporter assay. The Ubi-Cat construct showed titratable
responsiveness to CID treatment and was able to induce Wnt
reporter activity (Figure 7A). CID-mediated iLRP5 dimerization
also resulted in cytoplasmic stabilization of b-catenin (Figure 7A).
Next we examined transgene expression in Ubi-Cat mice. The
Ubi-Cat construct is coupled to a click beetle red-shifted luciferase
(CBR) reporter, permitting transgene expression detection via in
vivo bioluminescent imaging. Ubi-Cat mice demonstrated broad
iLRP5 expression via IVIS imaging (Fig. 7B). Moreover, iLRP5
expression via qRT-PCR was detected in multiple tissues of adult
mice (Figure 7C). Among the tissues examined, iLRP5
expression was highest in the pancreas, followed by testes,
mammary gland, spleen and prostate.
Figure 4. CK1 is required for iLRP5-mediated b-catenin activation. (A) 293 cells were co-transfected with 1 mg TCF-reporter and iLRP5
construct and incubated for 24 hours with indicated concentrations (nM) of MAPK (PD98059 (PD)), PI3K (wortmannin (Wort)), Akt (Akt-i), or casein
kinase 1 (CK1-i) inhibitor. (B) 293 cells were co-transfected with 1 mg NF-kB-reporter and hCD40 construct and incubated for 24 hours with indicated
nM concentrations of CK1-i plus hCD40L (1 mg/mL). SEAP activity was measured after an additional 24-hour incubation with or without 100 nM CID
(AP20187). Data is representative of at least two independent experiments. The amount of protein expression was normalized by anti-HA blot (a-HA).
doi:10.1371/journal.pone.0030814.g004
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+
Basal Epithelial Cells
One unique aspect of the Ubi-Cat mouse model is the putative
expression of the iLRP5 switch in various cell types within tissues.
Therefore, different cell types from a particular tissue could
potentially be purified for further analysis following Wnt signaling
induction. Analysis of Wnt signaling activation in fractionated cells
versus intact tissue should provide useful information about cell
autonomous versus non-cell autonomous influences in a particular
tissue. Due to multiple reports of a strong correlation between
increased Wnt signaling and prostate cancer [28], we initially
analyzed the outcome of iLRP5-mediated Wnt pathway induction
Figure 5. Two distinct regulatory sites in LRP5c are critical for function and localization of iLRP5. (A) (left) Schematic of LRP5c deletion
mutants (iLRP5 D1–5) comprised of synthetic ligand-binding domains (Fv9-Fvls). Numbers indicate N-terminal amino acid position of each deletion
mutant. Red and black lines represent indicated sequences and gray lines represent PPPSP motifs, respectively [24]. (right) Domain analysis of LRP5c
on Wnt/b-catenin signaling. 293 cells were transiently transfected with 1 mg each of indicated constructs along with TCF-SEAP reporter. After
24 hours, cell aliquots were treated with indicated concentrations of AP20187, and SEAP activity was measured after an additional 24-hour
incubation. Data represent two independent experiments with similar results. (B) Role of novel and CK1 sites in the interaction of Axin and iLRP5. 293
cells were transfected with 1 mg each of indicated mutants of iLRP5 along with an Axin expression construct. After 24-hour treatment with 100 nM
AP20187 (+CID), Axin was immunoprecipitated from whole cell lysates with anti-myc antibody (a-myc). Co-immunoprecipitation of LRP5c was
analyzed by anti-HA blot (a-HA). Amount of iLRP5 mutant expression was determined by HA blot (Input: a-HA). (C) Subcellular localization of iLRP5-
truncation mutants. 293 cells were transfected with 1 mg of indicated plasmids. Twenty-four hours after transfection, 100 nM FK1012 was added for
an additional 24 hours to induce dimerization. After fixation, cells were examined by fluorescence microscopy.
doi:10.1371/journal.pone.0030814.g005
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markers Lin
2, Sca-1
+, CD49f
+ (providing the moniker, LSC cells
[29]).
In order to demonstrate that CID-mediated induction of iLRP5
in LSCs promotes the activation of canonical Wnt target genes, we
performed qRT-PCR for known, canonical Wnt target genes,
including cyclin D1, c-myc, survivin and Axin2. iLRP5 activation
resulted in ,1.5-fold increase in steady state RNA for cyclin D1
and c-myc, and ,2-fold increase in survivin expression. However
Axin2 RNA levels were unaffected (Fig. 8A).
Next, we utilized LSCs from 6–8-week-old Ubi-Cat mice for in
vitro prostasphere assays as a surrogate assay for stem cell self-
renewal or in vivo prostate reconstitution experiments. Generally,
the in vitro assays are performed in the extracellular matrix
material, Matrigel
TM seeded with 1610
4 LSCs. CID-mediated
activation of iLRP5 resulted in consistent prostasphere enlarge-
ment (Fig. 8B), which paralleled our previous data obtained by
utilizing purified Wnt3a ligand [30]. Moreover, Wnt signaling
activation resulted in higher b-catenin staining and dispersal of
p63
+ cells (Fig. 8C). Cross-sectional analysis of iLRP5-induced
spheres revealed disruption of cellular organization of p63
+ cells.
In untreated prostaspheres, p63
+ cells generally reside on the outer
most cell layer, while the inner layers comprise mostly compacted
cells and are largely devoid of p63 expression. In contrast, iLRP
activation results in the generation of spheres comprising dispersed
p63
+ cells within all cell layers and the lack of cellular compaction
Figure 7. Analysis of iLRP5 expression in Ubi-Cat transgenic mice. (A) 293 cells were co-transfected with Ubi-Cat expression plasmid (0.5 mg)
along with TCF-SEAP reporter (0.2 mg). Cells were induced with AP20187 (100 nM) for 48 hours. Cell lysate and media were collected for examination
of iLRP5 activity. Western blot analysis indicates iLRP5-dependent stabilization of cytoplasmic b-catenin, consistent with accompanying SEAP reporter
assay. (B). Analysis of CBR expression via IVIS. (C) qRT-PCR analysis of iLRP5 expression in selected Ubi-Cat tissues using a transgene-specific primer-
probe set.
doi:10.1371/journal.pone.0030814.g007
Figure 6. A novel region of LRP5 (1516MFYSSNIPATVRPYRPY1531) is required for Wnt signaling. (A) Cross-species analysis of the novel
LRP5 (1516MFYSSNIPATVRPYRPY1531) sequence. (B) Membrane targeting of the cytoplasmic moiety of LRP5 (MF-LRP5) and three variants containing
mutations of possible phosphorylation sites: (1) YSSRFAA, (2) YRPYRFLPF and (3) YSSRFAA and YRPYRFLPF. The mutants have reduced Wnt
pathway inducibility. Western blot indicates comparable protein expression from respective TCF-SEAP assay. (C) Comparison of iLRP5 and iLRP5
mutants. YSSRFAA and YRPYRFLPF mutants have lower TCF-SEAP activity. The double mutant fails to activate Wnt signaling. Western blot indicates
protein expression from respective TCF-SEAP assay. (B and C), Data representative of two separate experiments performed in triplicates.
doi:10.1371/journal.pone.0030814.g006
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to phenocopy our previous observations utilizing Wnt3a ligand
[30,31].
In order to examine the cell-autonomous effects of iLRP5
activation in LSCs during prostate regeneration, we used a
prostate reconstitution assay. Multiple sub-Q grafts, containing
1610
5 WT LSC or Ubi-Cat LSCs and 1610
5 WT E18 rat-
derived urogenital sinus mesenchyme (UGSM) cells mixed in
Matrigel, were transplanted into the backs of CD1
nu/nu mice. The
LSC grafts were analyzed 8 weeks after transplantation. In the WT
control or Ubi-Cat-derived grafts in the absence of CID, glandular
structures were generally composed of simple monolayer struc-
tures; however, hyperplasia was widespread in CID-treated grafts
(Fig. 9A). iLRP5 activation in LSC grafts also resulted in
enhanced cyclin D1 staining, suggesting that iLRP5 activation
increases cyclin D1 activity (Fig. 9B). Analysis of p63 expression
revealed that there was a two-fold increase in the number of p63
+
cells in the iLRP5-induced, reconstituted grafts (Fig. 9C). Again,
in vivo observations based on iLRP5 activation in LSCs support
previously described results relying upon constitutively active b-
catenin [30], supporting the utility of iLRP5 as a Wnt-inducible
switch in prostate B/SCs.
Activation of iLRP5 in the Prostate Stroma Enhances
Prostate Reconstitution
Prostate homeostasis is maintained via balanced communication
between the stroma and the underlying epithelial compartment.
Therefore, we were interested in the effects of iLRP5 induction in
the prostate stroma. Since we have already established a working
model for in vivo prostate regeneration, we thought that this model
could potentially be useful to examine the effect of Ubi-Cat-
derived stroma in a developing prostate graft. Sca-1
+, CD49f
2,
Lin
2 Ubi-Cat prostate stromal cells (1610
5) were mixed with WT
LSCs (1610
5 cells) 1:1 in Matrigel. The grafts were subsequently
injected sub-Q into the backs of CD1
nu/nu mice followed by 8
weeks of CID treatment. Visual inspection and weight measure-
ment of the grafts indicated that the CID-treated samples were
physically larger and heavier (Fig. 10A). Cross-sectional analysis
of the grafts demonstrated that in the absence of CID or in control
reconstituted grafts using WT stoma and Ubi-Cat LSCs, prostate
acini were underdeveloped and lacking in prostate secretions.
However, in CID-treated grafts, the stroma was more densely
populated with cells and prostate ducts developed to a normal size
(,200 mm) that contained histologically normal prostate secretions
(Fig. 10B). The observed phenotype suggests that iLRP5 is
Figure 8. In vitro analysis of iLRP5 activation in prostate B/SCs.
(A) qRT-PCR analysis of Wnt target genes. LSCs were cultured in
Matrigel for 6 days with or without CID (100 nM). Cells were isolated
and RNA was collected for cDNA synthesis and qRT-PCR analysis. CID-
mediated iLRP5 activation promotes Wnt target genes expression. Error
bars represent StDev of 3 experiments, normalized to 18S RNA (B)
Prolonged (16 days) activation of iLRP5 promotes enlargement of
prostaspheres. Control spheres grew to maximum size of 150–200 mm;
however, CID-treated spheres grew to 300–400 mm. Bar=100 mm. (C)
Analysis of p63 and b-catenin expression in prostasphere cross-sections.
iLRP5 activation enhances b-catenin stability. CID-treated spheres reveal
dispersed distribution of p63
+ cells within all layers of prostasphere.
Bar=100 mm.
doi:10.1371/journal.pone.0030814.g008
Figure 9. Activation of iLRP promotes prostate hyperplasia in
the prostate reconstituted grafts. (A) H&E analysis of prostate
grafts. Activation of iLRP5 for 8 weeks resulted in formation of
hyperplastic acini in prostate grafts. Bar=100 mm. (B) Immunostaining
of prostate grafts using cyclin D1 antibody. Bar=50 mm( C) Immuno-
staining of prostate grafts using p63 antibody, Activation of iLRP5
resulted in over two-fold increase in the number of p63
+ cells. Data
representative of 9 +CID and 9 2CID grafts. Bar=50 mm.
doi:10.1371/journal.pone.0030814.g009
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activation of Wnt signaling in prostate stroma via iLRP5 is
sufficient to drive proper prostate development. These observa-
tions support an important role of Wnt signaling and its regulation
during prostate development with possible cell autonomous
functions in both basal LSCs and stromal cells.
Induction of iLRP5 in Ubi-Cat Mice
To examine the outcome of iLRP5 activation in intact prostate
tissue, a cohort of Ubi-Cat mice were treated bi-weekly with CID
(AP20187, 50 mg/mouse) for various durations. Animal cohorts
were treated starting at 6 weeks of age for 4, 8, 20, 36, 44, and 52
weeks and prostate were analyzed upon sacrifice. Despite low-
level, but prolonged b-catenin induction, treated mice appeared
healthy during the course of these studies. CID-mediated iLRP5
activation in vivo resulted in nuclear b-catenin localization by
immunostaining (Fig. S5). Activation of iLRP5 for up to 20 weeks
further resulted in a modest hyperproliferation of prostate
epithelial cells (Data not shown). Whereas age-matched,
untreated mice showed slight proliferation among ventral lobe
epithelial cells, treated mice reflected higher proliferative rates in
both ventral and the dorsal lobes. The epithelial cells developed
luminal hyperplasia and the normal single-cell layer organization
of luminal cells was replaced by hyperplasia. We also observed a
modest stromal thickening, consistent with reactive stroma.
Furthermore, the severity of the proliferative phenotype was
gradually enhanced with increased CID treatment, but not
apparent in age-matched, untreated mice.
Treatment of Ubi-Cat mice beyond 20 weeks resulted in an
even more prominent hyperproliferative phenotype in the ventral
and the dorsal lobes. Cells in the ventral lobe began to fill the
lumen and coincided with significant stromal thickening, as well as
a moderate level of acinar disorganization. Some nuclei were
hyperchromatic and atypical, appearing elliptical by H&E
analysis. Similarly, the dorsal lobes also demonstrated significant
epithelial proliferation and stromal thickening, which was so severe
in some foci that the stroma appeared to completely engulf the
epithelial compartment. Moreover, the majority of acini were
filled-in with epithelial and/or stroma cells (Fig. S6). After 52
weeks of CID treatment, two of six mice had developed prostate
adenocarcinoma, particularly in the ventral lobes. The ventral
lobe was extremely disorganized and the basement membrane was
severely disrupted or even absent in some acini (Figure 11). The
dorsal and the anterior lobes were also affected. The epithelial cells
had completely filled the lumens of the prostate ducts. In contrast,
age-matched WT and untreated Ubi-Cat mice appeared relatively
normal.
By utilizing the prostate gland as a model for analysis of Wnt
signaling induction in Ubi-Cat mice, we confirmed iLRP5 as a
useful inducible b-catenin switch. CID-dependent changes in the
prostatic lobes, from mild epithelial proliferation to adenocarci-
noma, supported the physiological relevance of iLRP5-mediated
Wnt signaling activation.
iLRP5 Wnt pathway induction drives mammary gland
hyperplasia and tumor formation
To better appraise the broader utility of the Ubi-CAT model,
we choose to examine the outcome of another tissue known to be
influenced by Wnt signaling. Maintenance of cellular homeostasis
in mammary epithelial cells is highly dependent on modulation of
Wnt signaling. Based on existing data, there appears to be a direct
correlation with deregulation of Wnt signaling and breast cancer
development [7,32]. In order to examine the physiological
relevance and functionality of iLRP5 in Ubi-Cat mice, we
explored the outcome of iLRP5-mediated Wnt signaling induction
in transgenic mammary cells. Mammary epithelial cells from 8-
Figure 10. Analysis of prostate reconstitution comprising adult
Ubi-Cat prostate stroma and WT LSCs. (A) Activation of iLRP5
increases size and weight of treated grafts. (B) Induction of iLRP5 in
prostate stroma enhances prostate regeneration in treated grafts. Data
representative of 6 +CID and 6 2CID grafts. Bar=200 mm.
doi:10.1371/journal.pone.0030814.g010
Figure 11. In vivo CID-mediated iLRP5 activation in the intact
prostate results in prostate tumor development. Treatment of
Ubi-Cat mice (n=6) with AP20187 starting at 6 weeks of age for 52
weeks leads to development of prostate adenocarcinoma (2 of 6). Age-
matched WT and untreated Ubi-Cat prostates (n=6) appeared normal.
Bar=200 mm.
doi:10.1371/journal.pone.0030814.g011
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week-old virgin female recipients. Each recipient was transplanted
with 5610
3 transgenic cells on the left side and an equivalent
number of WT cells on the right side. Transplanted mice were
treated twice weekly with the AP20187 (CID) for 8-weeks prior to
removal and analysis of grafted mammary cells. iLRP5-mediated
Wnt pathway induction resulted in hyperplasia in 4 of 6
transplanted grafts, two of which developed mammary tumors
(Fig. 12). This was in comparison to normal mammary
outgrowth observed in WT and untreated Ubi-Cat grafts. This
mammary transplant data confirm that activation of canonical
Wnt pathway signaling contributes to mammary gland hyperplasia
and that Ubi-Cat transgenic mice can be used as a source of cells
containing ligand-inducible ß-catenin expression.
Discussion
Although it is widely accepted that the canonical Wnt/b-catenin
signaling axis is initiated by Wnt-mediated Fz and LRP5/6
heterodimerization [33,34,35], key molecular details involved in
canonical Wnt signaling propagation remain elusive, such as the
details of how Dvl activates the dismantling of the destruction
complex. Bilic et al. demonstrated that Dvl plays an integral role in
clustering and phosphorylation of LRP6 and formation of the
LRP6-signalosome. By utilizing real-time confocal microscopy
they demonstrated that LRP6 aggregates in signaling foci within
15 min of Wnt stimulation, suggesting that oligomerization of
LRP6 is a prerequisite for Wnt signaling propagation. The
necessity for LRP6 clustering to promote Wnt signaling propaga-
tion provoked us to design an inducible Wnt system by marrying
the LRP5/6 signaling domain with CID technology. In a previous
study, Liu et al demonstrated that wild-type LRP6 also forms
spontaneous, Wnt-independent dimers; however, these dimerized
LRP6 subunits were inactive. Moreover, forced dimerization of
the cytoplasmic LRP6 domain inhibited its activity [36], although,
we also observed constitutive dimerization (or oligomerization) of
LRP5c (data not shown). In contrast to that study, our results show
that forced dimerization of LRP5c either at the plasma membrane
or within the cytosol is sufficient to induce b-catenin stabilization
(Fig. 1). Idiosyncrasies of the bulkier DNA gyrase B (30 kD)/
coumermycin CID system used by Liu et al, relative to FKBP12
(12 kD)-based dimerization, could account for these disparate
results. Consistent with our results, a separate study showed that
dimerization of a membrane-associated LRP6 intracellular
domain can stimulate signaling [37]. In addition, it has been
reported that Frizzled receptors can also dimerize following Wnt
binding, contributing to Wnt/b-catenin induction [38,39]. Taken
together, rather than inhibiting LRP5/6 signaling, these data
support the conclusion that oligomerization of LRP5 and other
Wnt-associated proteins can potentiate Wnt signaling.
Our study also reveals novel plasma membrane-distal aspects of
LRP5 function. It has been generally accepted that plasma
membrane localization of LRP5 precedes phosphorylation by
membrane-associated CK1a, which is required for Axin seques-
tration and b-catenin stabilization [35]. However, using non-
localized signaling domains and membrane-permeable ligands, we
unexpectedly discovered that dimerization of cytosolic LRP5 is
sufficient for localization to Dvl-containing punctate structures,
Axin-binding and canonical Wnt signaling. This indicates a link
between LRP5 oligomerization and recruitment to intra-cytoplas-
mic compartments that contain the Dvl/Axin complex. It is also
tempting to speculate that a similar mechanism can explain the
requirement for intracellular trafficking to an endosomal protein
complex by the Wingless (Wnt homologue) signaling complex in
Drosophila melanogaster that includes Arrow (LRP5 homologue) and
Dishevelled [40].
Amino-terminal deletion and site-directed mutagenesis analysis
of the cytoplasmic signaling domain of LRP5 revealed that a
previously unidentified region of LRP5 (1516MFYSSNIPATVR-
PYRPY1531), devoid of consensus CK1 phosphorylation sites, is
essential for b-catenin induction, and intra-cytoplasmic localiza-
tion. Nonetheless, we consistently observed that CK1 activity is
critical for LRP5 function. Since dimerization of iLRP5 within
intra-cytoplasmic compartments appears functionally intact, it is
likely that cytoplasmic CK1 isoforms, associated with Dvl/Axin
complexes, are able to induce LRP5 phosphorylation and
activation, comparable to membrane-bound CK1. However, it
remains to be tested what additional factor(s) target the newly
identified signaling domain required for iLRP5 signaling and
whether additional factor(s) are also critical for endogenous LRP5
function.
In addition to helping elucidate Wnt signaling mechanisms, our
initial in vitro data suggested that iLRP5 could also be utilized for
induction of Wnt signaling in vivo, justifying development of the
Ubi-Cat mouse model with widespread inducible b-catenin
signaling. Ubi-Cat mice should permit analysis of Wnt signaling
induction in multiple tissues, consistent with qRT-PCR-based
detection of iLRP5 in multiple tissues. The role of Wnt signaling
and the pro-neoplastic consequence of Wnt deregulation in
mammary and prostate tissues have been well documented
[7,10,13,41,42]. Therefore, we initially selected these two tissue
types to examine more carefully the utility of targeted iLRP5
signaling.
Figure 12. Mammary gland transplant assay using Ubi-Cat-
derived mammary cells. Ubi-Cat mammary cells were isolated from
6–8 week adult female Ubi-Cat mice. 5610
3 WT or Ubi-Cat mammary
cells were transplanted into virgin adult recipients. WT and untreated
Ubi-Cat cells demonstrated normal mammary outgrowth 8 weeks after
transplant. Activation of iLRP via AP20187 resulted in formation of
hyperplastic mammary ducts in 4 of 6 grafts. Two of six CID-treated
grafts formed mammary tumors.
doi:10.1371/journal.pone.0030814.g012
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we selected prostate B/SCs as our initial working model.
Activation of Wnt signaling in prostate progenitors results in the
induction of known canonical Wnt target genes, expansion of p63
+
cell population, enlargement of prostaspheres and development of
prostate hyperplasia [13,30,31]. Similarly, activation of iLRP5 in
LSCs promoted upregulation of known canonical Wnt target
genes, such as cyclin D1, c-myc and survivin. Prostasphere assays
indicated that iLRP5 activation results in the enlargement of
prostaspheres and expansion of the p63
+ cell population.
Moreover, prostate reconstitution assays using Ubi-Cat LSCs
revealed that activation of iLRP5 results in expansion of p63
+ cells
and increased cyclin D1 staining. We also observed increased
hyperplasia in iLRP5-induced grafts. In vivo activation of iLRP5 by
administering AP20187 to male Ubi-Cat mice resulted in the
progression of prostate tumor development from hyperplasia to
adenocarcinoma. Altogether, our in vitro and in vivo data involving
manipulation of Ubi-Cat LSCs and intact prostate, mirrors that of
previous reports on the effect of Wnt signaling in prostate
progenitors and tumorigenesis [10,13,30,31].
The prostate is a highly organized branched organ that relies on
coordinated communication between multiple signaling pathways,
such as Wnt, Notch, fibroblast growth factor (FGF) and
transforming growth factor b (TGF-b), for proper development.
Multiple studies have described the presence of activated canonical
Wnt signaling and its importance in prostate architecture
organization and cell specification during prostate development
and also androgen-dependent regeneration [13,31,43]. UGSM-
derived tissue provides a suitable niche for glandular development
due to its strong inductive characteristic [44], and hence UGSM
cells are regularly used for prostate reconstitution assays. Hence,
we also tested the effect of iLRP5-mediated Wnt pathway
activation within adult prostate stroma and its influence on
wildtype LSC cells during prostate reconstitution. Surprisingly,
induction of the iLRP5 switch in Ubi-Cat stroma enhanced
prostate tissue regeneration when compared to uninduced stromal
tissue. This observation emphasizes the importance of Wnt
signaling regulation during prostate development. It is likely that
iLRP5/Wnt signaling activation induces development-associated
signaling pathways that are know to act in a paracrine fashion,
such as Notch, FGF and TGF-b, in order to enhance prostate
regeneration. Future studies will more closely examine the possible
existence of such cross-regulations upon iLRP5 activation.
In this manuscript, we have provided two examples of Ubi-Cat-
derived tissues that can be manipulated using a single dimerizing
ligand. In addition to the effects of iLRP5 signaling in prostate
epithelial and stromal tissue, we also investigated the outcome of
iLRP5 induction within mammary cells. Mammary cell transplants
into the mammary fat pad also indicated the cell autonomous effects
of iLRP5 in mammary epithelial cells during development and
homeostasis. In this case, induction of iLRP5 resulted in the
formation mammary tumors, demonstrating that induction of
unaltered b-catenin is sufficient to drive mammary tumor progres-
sion. This result further demonstrates the potency and efficacy of the
iLRP5 switch as an inducer of the Wnt signaling pathway. Future
studies will investigate the role of canonical Wnt signaling in other
tissuesinbothreconstitutiontransplantmodelsand inintactUbi-Cat
mice. Additional animal models based on tissue-specific regulatory
elements or conditional, tissue-specific iLRP5 expression should
further broaden the utility of this technology.
Conclusions
Overall, this study has demonstrated the generation of a novel
inducible Wnt signaling switch by manipulating the Wnt
pathway co-receptor LRP5. We observed that membrane
recruitment of iLRP5 via CID leads to activation of the Wnt
signaling pathway. Oligomerization of LRP5 is also demonstrat-
ed to be a potent inducer of Wnt pathway induction,
independent of membrane recruitment. This observation led us
to generate an inducible Wnt switch (iLRP5) using only the
cytoplasmic domain of LRP5. The activation of iLRP5 is
achieved via CID technology, in which iLRP5-mediated Wnt
signaling induction is dependent on exposure to synthetic
homodimerizer drugs, like AP20187.
Next, we investigated the molecular and biochemical events
that follow upon iLRP5 activation, leading to Wnt signaling
activation. We were able to demonstrate that iLRP5 interacts
with Dvl; however, this interaction is not critical for the
downstream activity of iLRP5. Instead, the iLRP5 switch has
the ability to induce Wnt signaling by sequestering the Wnt
inhibitory molecule, Axin. The iLRP5/Axin interaction appears
sufficient to activate the Wnt pathway, even in the absences of
full-length Dvl, suggesting that iLRP5 does not require Dvl
activity or membrane localization. We also showed that iLRP5
phosphorylation via CK1 is required for proper iLRP5 activity.
Finally, we generated the Ubi-Cat transgenic mouse model. In
two distinct organ systems, Ubi-Cat mice demonstrated their
utility as a practical tool for investigating the effect of Wnt
signaling induction in vitro and in vivo.
Materials and Methods
Animals, cells, reagents, and constructs
All mice were housed at the Baylor College of Medicine (BCM)
Transgenic Mouse Facility in accordance with the guidelines of the
Institutional Animal Care and Use Committee (IACUC) for BCM.
This study was IACUC reviewed and approved within protocol
#AN-1428. HEK293 (ATCC, Manassas, VA) cells were main-
tained in DMEM, 10% FCS and antibiotics. Rapalog-B/AP22783
(Rap-B), FK1012 and AP20187 were provided by Ariad
Pharmaceuticals (Ariad Pharmaceuticals, Cambridge, MA). Rab-
bit anti-myc antibody (Covance/CRP), mouse anti-hemagglutinin
(HA) epitope (HA-11, Covance/CRP) and mouse anti-myc
antibody (9B11, Cell Signaling Technology, Danvers, MA) were
used for immunoprecipitation and Western blotting. A phospho-
specific anti-PPPSPP antibody was kindly provided by C Niehr
[24]. Cholera toxin B (CTx-B-TRITC) was used to detect
glycosphingolipid in membrane lipid-rafts (List Biological Labo-
ratories, Campbell, CA). The PI3-Kinase inhibitors wortmannin
(W), ERK inhibitor PD98059 (PD), Akt inhibitor (Akt-i) and casein
kinase inhibitor (CK1-I) were purchased from Calbiochem/EMD
Chemicals (San Diego, CA).
To generate TOP-SEAP and FOP-SEAP reporter plasmids,
the LEF-responsive promoter (‘‘TOP’’) and mutant LEF-
unresponsive promoter (‘‘FOP’’) from TOPflash or FOPflash
(Upstate Biotechnology/Millipore, Billerica, MA) were PCR-
amplified using N-terminal SalI-, and C-terminal NotI-linkered
primers and subcloned into XhoI/NotI-digested pWG018-SEAP.
Axin-myc and Dvl constructs were kindly provided by H
Varmus (MSKCC). Full-length human LRP5 and LRP6
constructs, pCDNA6-hLRP5 and pCDNA6-hLRP6, were kindly
provided by P McCrea (MDACC). The construction of Fyn-
myristoylated FRBl2( p B J 5 / M F-FRBl2-E) was previously de-
scribed [21]. For the construction of MF-LRP5c, the full-length
cytoplasmic domain of LRP5c (LRP51408–16165)w a sP C R -
amplified using N-terminal XhoI-, and C-terminal SalI-linkered
primers and subcloned in-frame into XhoI-SalId i g e s t e dp B J 5 /
MF-FRBl2-E.
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LRP5c (F3-GFP-LRP5c) and pSH1-Fv9-Fvls-LRP5c (iLRP5), PCR-
amplified LRP5c was subcloned into SalI-digested vectors pSH1-
FPK3, pSH1-FPK3-GFP or pSH1-Fv9-Fvls. All truncated LRP5c
mutants; iLRP5D1 (LRP51456–1616), iLRP5D2 (LRP51490–1616),
iLRP5D3 (LRP51515–1616), iLRP5D4 (LRP51532–1616) and iLRP5D5
(LRP51553–1616) were PCR-amplified using primers containing N-
terminal XhoI, and C-terminal SalI linkers and subcloned into the
SalI site of pSH1-Fv9-Fvls-E or the SalI site 39 of GFP in pSH1-FPK3-
GFP-E [20].
TCF-SEAP and NF-kB-SEAP (secreted alkaline
phosphatase) reporter assays.
SEAP reporter assays in HEK293 cells were carried out in 6- or
12-well plates as described previously with minor modifications
[21]. Briefly, HEK293 cells in 6-well plates were transfected with
1 mg of indicated plasmids along with TOP-SEAP reporter
plasmid (0.5–1 mg/well), FOP-SEAP or NF-kB-SEAP reporter
plasmid as a negative control using FuGene 6 reagent (Roche).
The following day, cells were washed and collected with 5 ml of
complete media and 200 ml aliquots were replated in triplicate in
96-well plates with indicated concentrations of CIDs or 50 ng/ml
of recombinant hCD40 ligand (R&D system, Minneapolis, MN)
and further incubated for ,24 h. For the inhibitor study,
HEK293 cells in 24-well plates were transfected with indicated
plasmids and were incubated with indicated concentration of each
inhibitor for 24 h. The following day, cells were washed and
further incubated with indicated concentrations of CIDs for
,24 h. Thereafter, supernatants were collected and analyzed for
SEAP activity. Briefly, saran wrapped plates were heat-inactivated
(HI) at 68uC for 459. 100 mL aliquots of HI supernatants were
mixed with 100 mL of 2 mM 4-methylumbilliferyl phosphate
(Sigma) in 2 M diethanolamine (Sigma) and fluorescence (Ex:355,
Em: 460 nm) was analyzed at various intervals. For each
experiment, we calculated the average of replicates and subtracted
background signals for non-transfected cell supernatants with
substrate.
Construction of transgene
The H2K-iLRP-I-CBR (Ubi-Cat) construct was generated in
multiple cloning steps. First, an EcoRV-NotI (blunt) 2-kb fragment
from H2K-I-LTR (kind gift of Dr. Jos Domen, Medical College of
Wisconsin) was cloned into BamHI-digested (and blunted) KBPA
vector to generate H2K-KBPA. Next, the 1.3-kb NotI-EcoRI
digested iLRP5 fragment was removed from the pSH1-S-Fv9Fvls-
LRP5-FLAGx2 construct. This fragment was cloned into NotI/
MunI-digested pSH1(Mn)-IRES-Lip (N,E) to get pSH1/iLRP5-
IRES. To obtain the reporter, we PCR-amplified the click beetle
red-shifted luciferase (CBR) reporter using primers, 5CBRX:
59-caagtcctcgagGTAAAGCGTGAGAAAAATGTCATC-39 and
3CBRE: 59-gacttgaattcTTACTAACCGCCGGCCTTCACC-39
to get the 1664-bp CBR (X,E) fragment. The amplified product
was digested via XhoI and EcoRI and the fragment was cloned into
XhoI (partial digest)/EcoRI-digested pSH1/iLRP5-IRES to
obtain pSH1/iLRP5-IRES-CBR. The NotI site was converted
to the EcoRI site using primers Not2Eco5: 59-ggccgcaagaattcaatc-
39 and Not2Eco3: 59-ggccgattgaattcttgc-39 to get pSH1(Nt)/
iLRP5-IRES-CBR. This 3.6-kb fragment was then cloned into
H2K-KBPA to get H2K/iLRP5-IRES-CBR. Transgene fragment
was isolated by SpeI restriction digest. The fragment was gel
purified using Qiagen gel purification kit (Qiagen, Valencia, CA).
The purified fragments were used for injection into FVB strain-
derived embryonic stem cells.
In vitro sphere cultures, sphere collection, RNA isolation,
qRT-PCR analysis and preparation of prostaspheres for
immunostaining
Ubi-Cat LSCs were cultured in Matrigel (BD Bioscience,
Franklin Lakes, NJ) as previously described [29]. LSCs were
cultured in prostate epithelial growth medium (PrEGM) (Lonza,
Walkersville, MD) or PrEGM supplemented with 100 nM
AP20187(Ariad Pharmaceuticals, Cambridge, MA). The media
was refreshed every two days. In order to isolate Matrigel-
embedded prostaspheres for gene expression or immunostaining
analysis, the cultures were treated with dispase (Stem Cell
Technologies, Vancouver, BC) for 45 min at 37uC. Spheres were
washed with cold PBS prior to subsequent analysis. RNA isolation
was performed using TRIzol (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions. The cDNA synthesis was
performed using qScript
TM cDNA Synthesis Kit (Quanta
Biosciences, Gaithersburg, MD), and qRT-PCR analysis was
performed using TaqManH Gene Expression Assay protocols
using an ABI Prism 7000 sequence detection system (Applied
Biosystems, Foster City, CA). For Immunostaining analysis,
isolated spheres where placed in histoGel (Lab Storage System
Inc., St. Peters, MO) and fixed for 10 min in 10% neutral
phosphate-buffered formalin then washed with 70% EtOH.
HistoGel ‘‘plugs’’ were embedded in paraffin and sectioned for
immunostaining analysis.
Prostate reconstitution assays
For in vivo reconstitution assays LSCs from 6–8 week-old adult
WT or Ubi-Cat mice were mixed with adult prostate stroma or E-
18 Rat UGSM. UGSM cells were prepared as described [29].
Ubi-Cat LSCs (1610
5) and 1610
5 UGSM or 1610
5 WT LSCs
and 1610
5 adult prostate stroma were mixed and pelleted by
centrifugation at 600 RCF. Pelleted cells were resuspended in
100 ml of Matrigel
TM (BD Bioscience) on ice. The Matrigel:Cell
mixture was injected subcutaneously into CD1
nu/nu mice. Mice
were treated with i.p. injection of AP20187 (Ariad Pharmaceuti-
cals) at 2 mg/kg in drug diluent (16.7% propanediol, 22.5%
PEG400, 1.25% TWEEN 80) or drug diluent alone twice a week
for 8 weeks. The grafts were isolated for further analysis.
Immunofluorescence (IF), Immunohistochemistry (IHC)
Formalin-fixed samples were embedded in paraffin and 5-mm
sections were deparaffinized and hydrated in 100% and 95%
EtOH steps and rinsed in water. Hydrated sections were stained
with hematoxylin and eosin (H&E). Prior to IF and IHC, Sodium
citrate (10 mM) antigen retrieval was performed, and sections
were blocked with goat serum or M.O.M (Vector Laboratories,
Inc. Burlingame, CA) kit for a minimum of 1 h at RT. When
performing IHC, cellular peroxidases were neutralized using 3%
H2O2 for 10 min. Sections were incubated with 1u antibody ON
at 4uC. Primary antibody dilutions were as follows: b-catenin
1:500 (Cell Signaling, Danvers, MA), p63 1:500 (Thermo Fisher
Scientific, Fremont, CA), cyclin D1 (SP4) (Thermo Fisher
Scientific, Fremont, CA). Secondary antibody incubation was
performed for 1 h at RT. Secondary antibodies (Invitrogen) were
donkey anti-mouse Alexa Fluor 599, goat anti-rabbit Alexa Fluor
488. the slides were overlaid with ProLongH Gold anti-fade
reagent with DAPI (Invitrogen).
For IHC, slides were incubated with secondary biotinylated
goat anti-rabbit (1:500 for 1 h at RT). Staining was performed by
treatment with ABC reagent for 45 min followed by DAB for
3 min (Vector Laboratories Inc., Burlingame, CA) and counter-
stained with hematoxylin.
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The iLRP5 mutants were generated by site-directed mutagen-
esis using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). Oligonucleotides for different iLRP5
mutants were designed according to the manufacturer’s protocol:
iLRP5-YSSRFAA, 59-GTACAACATGGACATGTTCTTCG-
CTGCAAACATTCCGGCCACTG CGAG-39; iLRP5-YR-
PYRFLPF, 59-CCGGCCACTGCGAGACCGTTCTTGCCC-
TTCATCA TTCGA GGA ATGGCG-39. (Bold characters
denote mutated nucleotides.)
iLRP5 Cross-Linking
HEK293 cells were transfected with 1.5 mg of iLRP5 via
FuGene 6 reagent (Roche) in 12-well format. 24-hr post-
transfection, iLRP5 was activated via 100 nM/ml of AP20187
for an additional 24-hr. Prior to cell lysis on the following day,
fresh AP20187 was added for an additional 2-hr. Cells were lysed
in 50 mL of mild detergent (20 mM MOPS, pH 7.2, 2 mM
EGTA, 10 mM MgCl2, 1% Triton X-100). Cell lysates were
crosslinked using 10 mM of disuccinimidyl glutarate (Thermo
Scientific, Rockford, IL) as suggested by the manufacturer.
Samples were analyzed via Western Blot analysis.
Statistical analysis
Statistical significance was determined based on the student t-
test between indicated groups.
Supporting Information
Figure S1 MF-LRP5/6 constitutively induces TCF/b-
catenin activity. (A) LiCl2-dependent, specific induction of
TCF4/b-catenin-responsive reporter, TCF-SEAP, activity. 293
cells were transiently transfected with 1 mg of TOP-SEAP, FOP-
SEAP reporter construct, or vector control. TOP-SEAP reporter
activity was measured 24 hours after administration of indicated
amounts of LiCl2.( B) Constitutive b-catenin induction by lipid raft
targeting of the intact intracellular domains of LRP5 and LRP6
(MF-LRP5c and MF-LRP6c) but not by the triple PPPSP domain.
293 cells were transiently transfected with 1 mg of myristoylated
EGFP (MF-EGFP), LRP5c (MF-LRP5c), LRP6c (MF-LRP6c), or
the triple PPPSP domain of LRP5 (MF-LRP5-3xPPPSP) along
with 1 mg of TOP-SEAP or FOP-SEAP reporter constructs.
Twenty-four hours after transfection, SEAP reporter activity was
measured. Data is representative of at least three independent
experiments.
(TIF)
Figure S2 Effect of Axin on MF-LRP5c-mediated b-
catenin activation. 293 cells were transiently transfected with
1 mg of TCF-SEAP reporter and 1 mgo fM F-GFP (-) or MF-
LRP5c expression vector along with indicated amounts (mg) of
myc-tagged Axin. TCF-SEAP activity was measured 24-hours
after transfection. The amount of protein expression was shown by
anti-Myc and anti-HA blotting (bottom). Data is representative of
at least three independent experiments.
(TIF)
Figure S3 Western blot analysis examining the expres-
sion of iLRP5/DIX, iLRP5/Axin and iLRP5/Dvl co-
transfection experiments. 293 cells were transfected with 1 mg
TCF-SEAP reporter along with 0.5 mg of iLRP5 and the indicated
amounts (mg) of dominant negative disheveled-FLAG (A) or Axin-
Myc constructs (B) or 0.5 mg disheveled-FLAG construct (C).
Twenty-four hours after transfection, 100 nM CID was added to
the cells and SEAP activity was measured following additional
24 h incubation. Cell lysate was obtained for Western blot
analysis. Actin probe was used to assess the overall protein load
in each lane.
(TIF)
Figure S4 (A, B). Constitutive phosphorylation of PPPSP
sites in iLRP5 mutants with or without dimerization. 293
cells were transfected with 1 mg of indicated mutants of iLRP5
along with 1 mg of the Axin expression construct. After 24-hour
treatment with 100 nM AP20187 (+CID), whole cell lysates were
immunoprecipitated with mouse anti-HA antibody (A, bottom) or
rabbit anti-Myc antibody (B, middle). Phosphorylation of PPPSP
sites in iLRP5 mutants (A, top) and co-immunoprecipitation of
LRP5 mutants with Axin (B, top) were analyzed by anti-pS1490
(A, a-pS1490) and anti-HA blot (B, a-HA). Axin was immuno-
precipitated from whole cell lysates with anti-Myc antibody (a-
Myc). Co-immunoprecipitation of LRP5c was analyzed by anti-
HA blot (a-HA). The amount of immunoprecipitated iLRP5
mutants (A, rabbit a-HA) and iLRP5 mutant expression (B) was
determined by HA blot (B, Input: a-HA).
(TIF)
Figure S5 iLRP5 promotes nuclear localization of b-
catenin in prostate epithelial cells. Cellular localization of b-
catenin in prostate tissue was analyzed via immunostaning. CID
mediated iLRP5 dimerization results in activation of canonical
Wnt singanling as suggested by presence of nuclear b-catenin
(arrow heads).
(TIF)
Figure S6 iLRP5 promotes prostate hyperplasia. Activa-
tion of iLRP5 in Ubi-Cat mice for 36–44 weeks promotes
proliferative phenotype within epithelial and stromal compart-
ment. The cellular proliferation is more prominent in the ventral
and dorsal lobes. Ventral and dorsal lobes demonstrate epithelial
proliferation and significant stromal thickening. Bar=200 mm.
(TIF)
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